Macrogenics (MGNX) Tops Q3 EPS by 7c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/13/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
MacroGenics Provides Update on Corporate Progress and Third Quarter 2019 Financial Results
November 6, 2019 4:01 PM ESTROCKVILLE, Md., Nov. 06, 2019 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today provided an update on its corporate progress and reported financial results for the quarter ended September 30, 2019.
MacroGenics most advanced programs are positioned to initiate or complete registration-directed studies over the next year, said Scott Koenig, M.D., Ph.D., President and CEO of MacroGenics. We look forward to presenting detailed data from the second interim OS analysis of SOPHIA, the Phase 3 study comparing... More
